Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

Rhea-AI Summary

Cassava Sciences, a clinical-stage biotechnology company focused on Alzheimer’s disease, announced its participation in B. Riley Securities’ Neuroscience Conference on April 27-28, 2022. Remi Barbier, CEO, will engage in a Q&A session on April 27 at 1:30 PM ET. The event will be streamed live, with a recording available for 90 days post-event on both the conference site and Cassava Sciences’ investor webpage.

The company is currently advancing its lead drug candidate, simufilam, through Phase 3 clinical studies for Alzheimer’s treatment.

- Q&A Session at Conference on Wednesday, April 27^th at 1:30PM Eastern -

AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022.

Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity research team on Wednesday, April 27, 2022, at 1:30 PM ET.

A webcast will be available on https://www.webcaster4.com/Webcast/Page/2875/45359 or in the Investors page of Cassava Sciences’ website for approximately 90 days following the event.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer’s disease, in Phase 3 clinical studies under Special Protocol Assessments from the FDA. Simufilam is also being tested in an open-label study and a randomized, double-blind, placebo-controlled Cognition Maintenance Study in patients with Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.

For More Information Contact:
Eric Schoen, Chief Financial Officer
eschoen@CassavaSciences.com
(512) 501-2450

FAQ

What event is Cassava Sciences participating in on April 27, 2022?

Cassava Sciences is participating in the B. Riley Securities’ Neuroscience Conference, a virtual event.

When will the Q&A session with Cassava's CEO take place?

The Q&A session with Cassava's CEO, Remi Barbier, will be held on April 27, 2022, at 1:30 PM ET.

What is the focus of Cassava Sciences' research?

Cassava Sciences focuses on developing solutions for Alzheimer's disease, specifically through their lead candidate simufilam.

How long will the webcast of the Q&A session be available?

The webcast will be available for approximately 90 days following the event.

What phase of clinical studies is simufilam currently in?

Simufilam, the lead drug candidate, is currently in Phase 3 clinical studies under Special Protocol Assessments from the FDA.